ARFGEF1 Knockout HEK293 Cell Line
Cat.No.:
EDC07529
Species:
Human
Cell Name:
HEK293
Gene:
ARFGEF1
Gene ID:
10565
Size:
1×10⁶cells
ARFGEF1 Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC07529 |
|---|---|
| Product Name | ARFGEF1 Knockout Cell Line(HEK 293) |
| Cell Line | HEK293 |
| Cellosaurus ID | CVCL_0045 |
| Cell Line Synonyms | Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 |
| Gene | ARFGEF1 |
| NCBI Gene ID | |
| Gene Synonyms | ARFGEP1|BIG1|DEDISB|P200 |
| Summary |
ADP-ribosylation factors (ARFs) play an important role in intracellular vesicular trafficking. The protein encoded by this gene is involved in the activation of ARFs by accelerating replacement of bound GDP with GTP. It contains a Sec7 domain, which may be responsible for guanine-nucleotide exchange activity and also brefeldin A inhibition. [provided by RefSeq, Aug 2011]
|
| Associated Diseases | Non-tumor |
| Morphology | Adherent |
| Passage Ratio | 1/5,2days |
| Complete Culture Medium | DMEM + 10% FBS |
| Freezing Medium | 95% Complete culture medium+ 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HEK293 | STR Info (Cell bank) Cell Line: HEK293 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1P0 | 12 | 11 | 12 | |
| D2S1338 | 19 | 19 | ||
| D3S1358 | 15 | 17 | 15 | 17 |
| D5S818 | 8 | 8 | 9 | |
| D7S820 | 11 | 12 | 11 | 12 |
| D8S1179 | 12 | 14 | 12 | 14 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 13 | 9 | 13 |
| D18S51 | 17 | 18 | 17 | 18 |
| D19S433 | 15 | 18 | 15 | 18 |
| D21S11 | 28 | 30.2 | 28 | 30.2 |
| FGA | 23 | 23 | ||
| Penta D | 9 | 10 | 9 | 10 |
| Penta E | 7 | 15 | 7 | 15 |
| TH01 | 7 | 9.3 | 7 | 9.3 |
| TPOX | 11 | 11 | ||
| vWA | 16 | 19 | 16 | 19 |
| D6S1043 | 11 | 11 | ||
| D12S391 | 19 | 21 | 11 | 15 |
| D2S441 | 11 | 15 | 11 | 15 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying ARFGEF1 function, ARFGEF1 Knockout HEK293 Cell Line or ARFGEF1 overexpression HEK293 Cell Line?
The choice depends on whether you are studying ARFGEF1 (BIG1)'s role as an Arf GTPase guanine nucleotide exchange factor or modeling its functions in Golgi trafficking. The Knockout line is the standard tool for asking whether ARFGEF1 is required for these processes — ARFGEF1/BIG1 is a Sec7-domain Arf GEF that activates Arf1/Arf3 GTPases at the trans-Golgi network for COP-I-independent vesicle formation; ARFGEF1 is closely related to ARFGEF2/BIG2; both are inhibited by ⭐ brefeldin A (the classical fungal toxin disrupting Golgi structure). Overexpression is useful for studying ARFGEF1 gain-of-function effects.
Important consideration: ARFGEF1 and ARFGEF2 share substantial substrate scope — single ARFGEF1 knockout may show modest phenotypes if ARFGEF2 compensates. Rescue with wild-type or catalytically-dead (E794K Sec7 domain glutamate finger) ARFGEF1 is the standard specificity control. The knockout is a critical specificity tool for brefeldin A research (BFA classically inhibits ARFGEF1/2; selective compounds AMF-26 and others are in development) and Golgi trafficking studies.
What are the application scenarios for this model?
Primary applications:
• Arf GTPase activation: Arf-GTP loading analysis in ARFGEF1-null cells.
• Brefeldin A specificity: critical genetic control for brefeldin A research given BFA inhibits ARFGEF1/2.
• Golgi morphology: TGN structure analysis given ARFGEF1's TGN trafficking role.
• ARFGEF1/2 paralog dissection: ARFGEF2 expression analysis to interpret ARFGEF1-specific functions.
EDITGENE recommends this model for researchers investigating Arf GEF biology and brefeldin A pharmacology.
Is this ARFGEF1 Knockout HEK293 Cell Line compatible with overexpression rescue experiments?
Yes. ARFGEF1 rescue experiments are well-established for Arf GEF research:
• Construct design: use a codon-modified ARFGEF1 sequence with a small C-terminal tag (FLAG, HA). ARFGEF1 has DCB, HUS, Sec7 (catalytic), HDS1-3 domains — preserve all elements.
• Catalytically-dead rescue: E794K mutation in the Sec7 domain catalytic glutamate finger abolishes Arf-GEF activity.
• Brefeldin A-resistant rescue: F190Y mutation in the Sec7 domain confers BFA resistance, enabling on-target BFA validation.
• Functional readout: rescue should restore Arf-GTP loading and Golgi structure.
HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
download